Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
International Journal of Nephrology and Renovascular Disease
JournalCitation impact & published research
International Journal of Nephrology and Renovascular Disease is a journal indexed in ScholarIQ from OpenAlex. ScholarIQ records 554 works, 12,594 citations, an h-index of 52 and an APC (USD) of 2,320.
554
Works
12,594
Citations
52
h-index
2,320
APC (USD)
IDs:OpenAlex
What are the most-cited papers on International Journal of Nephrology and Renovascular Disease?
ScholarIQmost cited works
Vascular access for hemodialysis: current perspectives
Domenico Santoro, Filippo Benedetto, Placido Mondello, Francesco Spinelli, Carlo Alberto Ricciardi, Valeria Cernaro, Michele Buemi, Narayana Pipitò, David Barillà
International Journal of Nephrology and Renovascular Disease. 2014361 CitationsOPEN ACCESS
Rodent models of diabetic nephropathy: their utility and limitations
Munehiro Kitada, Yoshio Ogura, Daisuke Koya
International Journal of Nephrology and Renovascular Disease. 2016239 CitationsOPEN ACCESS
Tolvaptan in the treatment of autosomal dominant polycystic kidney disease: patient selection and special considerations
Laia Sans-Atxer, Dominique Joly
International Journal of Nephrology and Renovascular Disease. 201844 CitationsOPEN ACCESS
<p>Optimal management of atypical hemolytic uremic disease: challenges and solutions</p>
Rupesh Raina, Manpreet Kaur Grewal, Yeshwanter Radhakrishnan, Vineeth Tatineni, Meredith DeCoy, Linda Burke, Arvind Bagga
International Journal of Nephrology and Renovascular Disease. 201932 CitationsOPEN ACCESS
Is the light at the end of the tunnel nigh? A review of ADPKD focusing on the burden of disease and tolvaptan as a new treatment
Rashid A. Barnawi, Rahaf Zyad Attar, Sultan Alfaer, Osama Safdar
International Journal of Nephrology and Renovascular Disease. 201821 CitationsOPEN ACCESS
Related on ScholarIQ
Vascular access for hemodialysis: current perspectives
Paper
Rodent models of diabetic nephropathy: their utility and limitations
Paper
Tolvaptan in the treatment of autosomal dominant polycystic kidney disease: patient selection and special considerations
Paper
<p>Optimal management of atypical hemolytic uremic disease: challenges and solutions</p>
Paper
Is the light at the end of the tunnel nigh? A review of ADPKD focusing on the burden of disease and tolvaptan as a new treatment
Paper
Disconnect in Assessments of Autosomal Dominant Polycystic Kidney Disease Burden Between Patients and Physicians: A Survey Study
Paper